SCHEMBL24430116

SCHEMBL24430116

COc1ccc(N2C(=O)C=C(Nc3cc(F)c(O)c(F)c3)C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ MAPT P10636 6/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ HSD17B3 P37058 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HPGD P15428 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ ESR1 P03372 1/20 0.42
▸ MGLL Q99685 1/20 0.41
▸ GAA P10253 3/20 0.39
▸ RECQL P46063 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205848 0.89 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24430113 0.87 MEN1 (0.54) ALDH1A1KDM4EMAPTHSD17B3MEN1
SCHEMBL24430003 0.87 MEN1 (0.43) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24430074 0.86 MEN1 (0.50) ALDH1A1KDM4ENPC1RAB9AHSD17B3
SCHEMBL24430026 0.86 KMT2A (0.52) ALDH1A1KDM4EMAPTHSD17B3MEN1
SCHEMBL24437318 0.86 RPS6KA3 (0.47) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24429997 0.86 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24437357 0.86 MEN1 (0.45) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24430021 0.86 MEN1 (0.45) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL24430079 0.86 MEN1 (0.45) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109067-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease UAB RESEARCH FOUNDATION 2022-05-19 — — US disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 ALDH1A1 703/4885KDM4E 960/4885MAPT 4168/4885
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS ALDH1A1 671/4885KDM4E 2869/4885MAPT 4076/4885
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS ALDH1A1 671/4885KDM4E 2869/4885MAPT 4076/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 ALDH1A1 703/4885KDM4E 960/4885MAPT 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback